Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Argatroban (Argipidine) – US – Federal Circuit affirms validity of Argatroban patent, Japanese translation issue: Mitsubishi Chemical Corp. v. Barr Labs. (Orange Book Blog) (IPBiz) (Patent Docs)

US: Federal Circuit decision in Association for Molecular Pathology v. U.S. Patent and Trademark Office (Myriad) (Intellectual Property Law Blog) (Patently-O) (Patent Docs) (Patent Docs) (IPblog) (IPKat)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Medical Patent Law – a special offer (IP Think Tank)

BIO2011: Robert Cantrell on “All Fins On” (Patent Baristas)

Will gene patents impede whole genome sequencing? Deconstructing the myth that 20% of the human genome is patented (Holman’s Biotech IP Blog)

Sturm und Drang: The TPP agreement and biologics exclusivity (FDA Law Blog)

EU: Medeva and the interpretation of EU law: literal or teleological? (The SPC blog)

EU: “Déjà vu at the ECJ?”: a note on Neurim (The SPC blog)

France: The end of the reform on the appearance of generic drugs and IPR (Class 46)

Spain: A SHED OF LIGHT IN THE DARK: First Spanish decision admitting post-grant claim limitations under article 138.3 of CPE 2000: Sanofi-Aventis v. Hospira (Kluwer Patent Blog)

US: Federal Circuit decision in Association for Molecular Pathology v. U.S. Patent and Trademark Office (Myriad) (Intellectual Property Law Blog) (Patently-O) (Patent Docs) (Patent Docs) (IPblog) (IPKat) (ArsTechnica)

US: FDA looks to multiple sources, including EMA Guidelines, in developing biosimilar approval standards (Patent Docs)

US: BIO: Unleashing the promise of biotechnology (pt. 3) (Patent Baristas)

 

Products

Arava (Leflunomide) – Australia: Pharmaceuticals – copyright in PIs and indirect patent infringement: Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (IP Whiteboard)

Argatroban (Argipidine) – US – Federal Circuit affirms validity of Argatroban patent, Japanese translation issue: Mitsubishi Chemical Corp. v. Barr Labs. (Orange Book Blog) (IPBiz) (Patent Docs)

Fasudil – Asahi award reduced in Fasudil licensing dispute with Actelion (Patent Docs)

Gemzar (Gemcitabine) – US: ALJ Rogers rules on motion for a presumption of infringement and motion to compel in Certain Gemcitabine (337-TA-766) (ITC 337 Law Blog)

Gemzar (Gemcitabine) – US: ALJ Rogers rules on motion to quash and/or limit subpoenas in Certain Gemcitabine (337-TA-766) (ITC 337 Law Blog)

Imitrex (Sumatriptan succinate) – FDA approval of generic Imitrex statdose sheds some light on auto-injector “sameness” issues – But what about other combination products? (FDA Law Blog)

Lipitor (Atorvastatin) – The fight for Atorvastatin: further news (The SPC blog)

Nexium (Esomeprazole magnesium) – US: Patent infringement complaint filed following a Paragraph IV certification: Astrazeneca AB et al. v. Hetero Drugs, Ltd., Unit III et al. (Patent Docs)

Prezista (Darunavir) – US: Patent infringement complaint filed following a Paragraph IV certification: Tibotec Inc. et al. v. Lupin Ltd. et al. (Patent Docs)

Relpax (Eletripian hydrobromide) – Pfizer settles Relpax infringement suit with Apotex (Patent Docs)

Solodyn (Minocycline) – US: Medicis and Lupin settle Solodyn infringement dispute; Agree to drug development collaboration (Patent Docs)

Viagra (Sildenafil citrate) – US: Patent infringement complaint filed following a Paragraph IV certification: Pfizer Inc. et al. v. Hetero Drugs Ltd. et al. (Patent Docs)